Skip to main content
. 2026 Sep 8;21(1):101880. doi: 10.1016/j.jcmgh.2026.101880

Figure 1.

Figure 1

The deletion of Bcl-xL reduces tumor burden in Apc-deficient tumors. (A) Gene construction schema in each mouse model (WT, M-B, M-A, and M-AB mice). (B) The protocol schema of TAM administration. (C) Bcl-xL staining in WT and M-B mice. Yellow arrows indicate the glands without Bcl-xL expression. The rates of the Bcl-xL+ cells are quantified (n = 3 mice/group). The P value was calculated using a t test. (D) Macroscopic findings of gastric tumors in M-A and M-AB mice. Tumor area is surrounded by a yellow dotted frame. The tumor diameters are quantified (n = 6 mice/group). The P value was calculated using a t test. (E) Hematoxylin and eosin (H&E) staining of WT, M-B, M-A, and M-AB mice at antrum (representative images for n = 3 mice/group). (F) Red fluorescent protein (RFP) staining in WT, M-B, M-A, and M-AB mice (representative images for n = 3 mice/group). (G) RT-PCR of Bcl2l1 (Bcl-xL) expression in WT, M-B, M-A, and M-AB mice (n = 9/group). The P value was calculated using a t test. Scale bars, 100 μm. Mean ± standard error of the mean. ∗P < .05.